Role of angiotensin-converting enzyme inhibitors in reducing cardiovascular and cerebral complications in chronic kidney disease: focus perindopril
https://doi.org/10.17650/1818-8338-2020-14-3-4-K601
Abstract
In the development of renocardial relationships in chronic kidney disease, an important role is given to the activation of the renin-angiotensin-aldosterone system (RAAS), as the main component of the progression and development of cardiovascular complications..The presented review is devoted to the analysis of modern scientific data on the effect of high RAAS activity in chronic kidney disease on the course and prognosis of cardiovascular complications, as well as the protective capabilities of angiotensin-converting enzyme inhibitors, in particular perindopril. The results of scientific research on the role of the RAAS in the progression of chronic kidney disease are summarized. Data on chronic kidney disease as a risk factor for cardiovascular and cerebral complications are presented. Attention is focused on the possibilities of prolonging the pre-dialysis period of chronic kidney disease when using angiotensin-converting enzyme inhibitors. The role of perindopril as a lipophilic angiotensin-converting enzyme inhibitor with a high affinity for tissue RAAS was emphasized in reducing cardiovascular and cerebral risk in chronic kidney disease.
About the Author
I. T. Murkamilov
Kyrgyz State Medical Academy named after I. K. Akhunbaev; Kyrgyz Russian Slavic University
Kyrgyzstan
92 Akhunbaev St., Bishkek 720020
44 Kievskaya St., Bishkek 720000
Kyrgyzstan
92 Akhunbaev St., Bishkek 720020
44 Kievskaya St., Bishkek 720000
References
1. Schalekamp M.А., Danser A.H. Angiotensin II production and distribution in the kidney-II. Model-based analysis of experimental data. Kidney Int 2006;69(9):1553–7. DOI: 10.1038/sj.ki.5000305.
2. Bruneval P., Hinglais N., Alhenc-Gelas F. et al. Angiotensin I converting enzyme in human intestine and kidney. Histochemistry 1986;85(1):73–80. DOI: 10.1007/BF00508656.
3. Burns K.D., Li N. The role of angiotensin II-stimulated renal tubular transport in hypertension. Curr Hypertens Rep 2003;5(2):165–71. DOI: 10.1007/s11906-003-0074-1.
4. Turakhia M.P., Blankestijn P.J., Carrero J. et al. Chronic kidney disease and arrhythmias: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. Nephrology(SaintPetersburg) 2019;23(2):18–40. DOI: 10.24884/1561-6274-2019-23-2-18-40 (In Russ.)
5. Satou R., Penrose H., Navar L.G. Inflammation as a Regulator of the ReninAngiotensin System and Blood Pressure. Curr Hypertens Rep 2018;20(12):100. DOI: 10.1007/s11906-018-0900-0.
6. Siragy H.M., Carey R.M. Role of the intrarenal renin-angiotensin-aldosterone system in chronic kidney disease. Am J Nephrol 2010;31(6):541–50. DOI: 10.1159/000313363.
7. Mukhin N.A., Milovanov Yu.S., Kozlovskaya L.V. et al. The serum level of the morphogenetic protein fibroblast growth factor 23(FGF-23) as a marker for the efficiency of hyperphosphatemia therapy with phosphate-binding agents in chronic kidney disease. Therapevticheskiy archiv = Therapeutic archive 2016;4(88):41–5. DOI: 10.17116/terarkh201688441-45. (In Russ.).
8. Batyushin M.M., Kastanayan A.A., Rudenko L.I., Chistyakov V.A. Fibroblast growth factor 23. Physiological role and participation in vascular calcification in chronic renal failure. Zhurnal fundamentalnoi meditsiny i biologii = The journal of fundamental medicine and biology 2014;2:4–8. (In Russ.).
9. Sie M.P., Yazdanpanah M., MattaceRaso F.U. et al. Genetic variation in the renin-angiotensin system and arterial stiffness. The Rotterdam Study. Clin Exp Hypertens 2009;31(5):389–99. DOI: 10.1080/10641960802668706.
10. Moiseev V.C., Mukhin N.A. Cardiovascular risk and chronic kidney disease: cardio- and nephroprotection strategies. Klinicheskaia nefrologiia = Clinical nephrology 2014;2:4–29. (In Russ.).
11. KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease. Kidney Int (Suppl.) 2013;3(3):259–305.
12. Goupil R., Lamarre-Cliche M., Vallée M. The 2017 American College of Cardiology/American Heart Association vs Hypertension Canada high blood pressure guidelines and potential implications. Can J Cardiol 2018;34(5): 665–9. DOI: 10.1016/j.cjca.2018.01.011.
13. Gapon L.I. Angiotensin converting enzymeinhibitor Perindopril in arterial hypertension andrenal failure. Arterial’naya gipertenziya = Arterial Hypertension 2010;16(5):457–63. (In Russ.). DOI: 10.18705/1607-419X-2010--5-.
14. Go A.S., Chertow G.M., Fan D. et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351(13):1296–305. DOI: 10.1056/NEJMoa041031.
15. Protasov K.V., Dzizinsky A.A., Sinkevich D.A. Aortic rigidity: Clinical and pathogenetic interrelations with myocardial affection in patients with isolated systolic and systolic diastolic arterial hypertension. Biulleten VSNTS SO RAMN = Bulletin of the East Siberian scientific center of the Siberian branch of the Russian medical Academy of Sciences 2006;2(48):192–8. (In Russ.).
16. Koens M.J., Krasznai A.G., Hanssen A.E. et al. Vascular replacement using a layered elastin-collagen vascular graft in a porcine model: one week patency versus one month occlusion. Organogenesis 2015;11(3):105–21. DOI: 10.1080/15476278.2015.1038448.
17. Drapkina O.M., Mandzhieva B.A. A vessel age. Mechanisms of vessel wall ageing. Methods of assessment. Kardiovaskuliarna ia terapiia i profilaktika = Cardiovascular Therapy and Prevention 2014;13(5):74–82. (In Russ.). DOI: 10.15829/1728-88002014-5-74-82.
18. Sinkevich D.A., Protasov K.V., Dzizinsky A.A. The concept of “vascular age” as a new approach to the cardiovascular risk assessment. Sibirskii meditsinskii zhurnal (Irkutsk) = Siberian medical journal (Irkutsk) 2011;6:9–13.
19. Murkamilov I.T., Sabirov I.S., Fomin V.V. et al. Correlations between parameters of central hemodynamics and cytokine profile in chronic kidney disease in combination with cerebrovascular diseases. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry 2019;119(6): 65–71. (In Russ.). DOI: 10.17116/jnevro201911906165.
20. Murkamilov I.T., Sabirov I.S., Murkamilova Z.A. et al. Stratification of nephrocerebral and cardiovascular risk in chronic glomerulonephritis (literature review). Arkhivie vnutrennei meditsiny = The Russian Archives of Internal Medicine 2018;8(6):418-423. (In Russ.). DOI: 10.20514/2226-6704-2018-8-6418-423.
21. Karpov Y.A. Perindopril arginine: a new ACE inhibitor salt increases therapeutic potential. Kardiovaskuliarnaia terapiia i profilaktika = Cardiovascular Therapy and Prevention 2008;7(6):64–72. (In Russ.).
22. Drapkina O.M. Angiotensin converting enzyme inhibitors in patients with coronary artery disease. Arterial’naya Gipertenziya = Arterial Hypertension 2011;17(1):79–82. (In Russ.). DOI:10.18705/1607-419X-201--1-.
23. Chazova I.E., Zhernakova Yu.V. Оn behalf of the experts. Clinical guidelines. Diagnosis and treatment of arterial hypertension. Sistemnye gipertenzii = Systemic Hypertension 2019;16(1):6–31. (In Russ.). DOI: 10.26442/2075082X.2019.1.190179.
24. Tropeano A.I., Boutouyrie P., Pannier B. et al. Brachial pressure-independent reduction in carotid stiffness after longterm angiotensinconverting enzyme inhibition in diabetic hypertensives. Hypertension 2006;48(1):80–6. DOI: 10.1161/01.HYP.0000224283.76347.8c.
25. Mitchell G.F., Dunlap M.E., Warnica W. et al. Prevention of Events with Angiotensin-Converting Enzyme Inhibition Investigators. Longterm trandolapril treatment is associated with reduced aortic stiffness: the prevention of events with angiotensinconverting enzyme inhibition hemodynamic substudy. Hypertension 2007;49(6):1271–7. DOI: 10.1161/HYPERTENSIONAHA.106.085738.
26. Mitchell G.F., Izzo J.L., Lacourcire Y. et al. Omapatrilat reduces pulse pressure and proximal aortic stiffness in patients with systolic hypertension: results of the conduit hemodynamics of omapatrilat international research study. Circulation 2002;105(25):2955–61. DOI: 10.1161/01.CIR.0000020500.77568.3C.
27. Schoolwerth A.C., Sica D.A., Ballermann B.J. et al. Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Circulation 2001;104(16):1985–91. DOI: 10.1161/hc4101.096153.
28. Zheng C.M., Wang J.Yi., Chen T.T. et al. Angiotensin-converting enzyme inhibitors or angiotensin receptor blocker monotherapy retard deterioration of renal function in Taiwanese chronic kidney disease population. Sci Rep 2019;9(1):2694. DOI: 10.1038/s41598-019-38991-z.
29. Podzolkov V.I., Osadchy K.K. ACE inhibitors in arterial hypertension treatment: focus on lisinopril. Ratsionalnaia farmakoterapiia v kardiologii = Rational pharmacotherapy in cardiology 2009;1:57–62. (In Russ.).
30. Konradi A.O. Rational choice of an ACE inhibitor, from the standpoint of the renoprotection. Arterial’naya gipertenziya = Arterial Hypertension 2004;10:177–80. (In Russ.).
31. Ivanov D.D. Microalbuminuria: a look of nephrologist. Zdorov’e Ukrainy = Health of Ukraine 2008; 21/1:18–9. (In Russ.).
32. Nishijama K., Igari T., Nanda S., Ishii M. Long-term effects of delapril on renal function annd urinary excretion of kallikrein, prostaglandin E2, and thromboxan B2 in hypertensive patients. Am J Hypertens 1991;4(1 Pt 2):52–3. DOI: 10.1093/ajh/4.1.52S.
33. Matsuda H., Hayashi K., Wakino S. et al. Role of endothelium-derived hyperpolarizing factor in ACE inhibitor-induced renal vasodilation in vivo. Hypertension 2004;43(3):603–9. DOI: 10.1161/01.HYP.0000118053.42262.71.
34. Storzhakov G.I., Tomilina N.A., Shilo V.Yu. et al. The congestive heart failure in patients with the chronic renal failure. Serdechnaya nedostatochnost’ = Heart failure 2005;3:100–4. (In Russ.).
35. Mukhin A.V., Fomin V.V., Moiseev S.V. et al. Microalbuminuria – an integral marker of cardiorenal relations in arterial hypertension. Consilium Medicum 2007;9(5):13–9. (In Russ.).
36. Bobkova I.N., Kozlovskaya L.V., Cygin A.N., Shilov E.M. Clinical practice guidelines for diagnosis and treatment membranous nephropathy. Nefrologiia = Nephrology (Saint-Petersburg) 2014;18(4):93–100. (In Russ.).
37. Ceconi C., Fox K., Remme W.J. et al. ACE inhibition with perindopril and endothelial dysfunction. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc Res 2007;73(1):237–46. DOI: 10.1016/j.cardiores.2006.10.021.
38. Levey A.S., Coresh J., Balk E. et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003;139(7):137–47. DOI: 10.7326/0003-4819-139-2200307150-00013.
39. Zhang Y., He D., Zhang W. et al. ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3–5: A Network Meta-Analysis of Randomised Clinical Trials. Drugs 2020;80(8):797–811. DOI: 10.1007/s40265-020-01290-3.
40. Pfeffer M.A., Braunwald E., Moye L.A. et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992;327(10):669–77. DOI: 10.1056/NEJM199209033271001.
41. SOLVD Investigators, Yusuf S., Pitt B. et al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325(5): 293–302. DOI: 10.1056/NEJM199108013250501.
42. Remme W.J., Deckers J.W., Fox K.M. et al. Secondary prevention of coronary disease with ACE inhibition – does blood pressure reduction with perindopril explain the benefits in EUROPA?. Cardiovasc Drugs Ther 2009;23(2):161–70. DOI: 10.1007/s10557-008-6143-6.
43. Perkovic V., Ninomiya T., Arima H. et al. Chronic kidney disease, cardiovascular events, and the effects of perindoprilbased blood pressure lowering: data from the PROGRESS study. J Am Soc Nephrol 2007;18(10):2766–72. DOI: 10.1681/ASN.2007020256.
44. Qaseem A., Hopkins R.H. Jr., Sweet D.E. et al. Clinical Guidelines Committee of the American College of Physicians. Screening, monitoring, and treatment of stage 1 to 3 chronic kidney disease: A clinical practice guideline from the American College of Physicians. Ann Intern Med 2013;159(12):835–47. DOI: 10.7326/0003-4819-159-12201312170-00726.
45. Brugts J.J., Ferrari R., Simoons M.L. Angiotensin-converting enzyme inhibition by perindopril in the treatment of cardiovascular disease [published correction appears in Expert Rev Cardiovasc Ther 2009 Jun;7(6):722]. Expert Rev Cardiovasc Ther 2009;7(4):345–60. DOI: 10.1586/erc.09.2.
46. Alfakih K., Hall A.S. Drug evaluation of perindopril. Expert Opin Pharmacotherapy 2006;7(1):63–71. DOI: 10.1517/14656566.7.1.63.
47. Ceconi C., Francolini G., Olivares A. et al. Angiotensin-converting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE. Eur J Parmacol 2007;577(1–3):1–6. DOI: 10.1016/j.ejphar.2007.07.061.
48. Ceconi C., Francolini G., Bastianon D. et al. Differences in the effect of angiotensinconverting enzyme inhibitors on the rate of endothelial cell apoptosis in vivo and in vivo studies. Cardovasc Drugs Ther 2007;21(6):423–9. DOI: 10.1007/s10557-007-6068-5.
49. Turnbull F., Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362(9395):1527–35. DOI: 10.1016/s0140-6736(03)14739-3.
50. Sycheva Y.A., Kirsanov A.I. Impairment of the renal function and its correction with perindopril in ischemic heart disease patients with heart failure. Nefrologiia = Nephrology(Saint-Petersburg) 2003;7(2): 62–6. (In Russ.). DOI: 10.24884/15616274-2003-7-2-62-66.
51. Bots M.L., Remme W.J., Lüscher T.F. et al. ACE inhibition and endothelial function: main findings of PERFECT, a sub-study of the EUROPA trial. Cardiovasc Drugs Ther 2007;21(4): 269–79. DOI: 10.1007/s10557-007-6041-3.
52. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack [published correction appears in Lancet 2001 Nov 3;358(9292):1556] [published correction appears in Lancet 2002;359(9323):2120]. Lancet 2001;358(9287):1033–41. DOI: 10.1016/S0140-6736(01)06178-5.
53. Drobotya N.V., Guseinova E.S., Malakhov M.V., Pirozhenko A.A. Comparative effects of antihypertensive therapy modes on the wall rigidity of various blood vessels. Arterial’naya gipertenziya = Arterial Hypertension 2016;22(2):217–26. (In Russ.). DOI: 10.18705/1607-419X2016-22-2-217-226.
54. Logacheva I.V., Ivanova I.V., Pocheptsova L.V. Vascular and organoprotective properties of fixed combination of perindopril/indapamid in hypertensive patients. Arterial’naya gipertenziya = Arterial Hypertension 2009; 15(3):300–8. (In Russ.). DOI: 10.18705/1607-419X-2009-15-3-300-308.
55. Heerspink H.J., Ninomiya T., Perkovic V. et al. Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease. Eur Heart J 2010;31(23):2888–96. DOI: 10.1093/eurheartj/ehq139.
56. Seleznev S.V., Yakushin S.S. Efficiency of perindopril arginine and indapamide retard in patients with nocturnal hypertension: The results of the study “Chronos”. Arterial’naya gipertenziya = Arterial Hypertension 2018;24(2):237–45. (In Russ.). DOI: 10.18705/1607-419X-2018-24-2-237-245.
57. Shiganov S.V., Bayev V.V., Kapitonov V.F. Clinical and economic analysis: fixed combination perindopril arginine/ indapamide retard versus “traditional treatment” in hypertensive patients with renal insufficiency. Arterial’naya Gipertenziya = Arterial Hypertension 2013;19(5):442–8. (In Russ.). DOI: 10.18705/1607-419X-2013-19-5-442-448.
Review
For citations:
Murkamilov I.T. Role of angiotensin-converting enzyme inhibitors in reducing cardiovascular and cerebral complications in chronic kidney disease: focus perindopril. The Clinician. 2020;14(3-4):78-85. (In Russ.) https://doi.org/10.17650/1818-8338-2020-14-3-4-K601
Views:
819
Email this article 